Labopharm is an international, specialty pharmaceutical company focused on improving existing drugs by incorporating its proprietary, advanced controlled-release technologies. Labopharm's lead product, a once-daily formulation of the pain-killer tramadol designed to address the worldwide market for moderate to severe pain, has been approved in Europe and is currently the subject of a New Drug Application, or NDA, under review by the US FDA. Labopharm is developing additional product candidates using their drug delivery technologies and formulation expertise and have three product candidates in the clinical stage of development including a once-daily formulation of trazodone. In addition Labopharm is currently pursuing tramadol product line extensions, including combination products using their Contramid technology.

Company was acquired by Paladin Labs, Inc.